Results for knoglemarvssvigt translation from Danish to English

knoglemarvssvigt.
bone marrow failure.

agranulocytose, knoglemarvssvigt
agranulocytosis, bone marrow failure

knoglemarvssvigt, lymfadenopati, eosinofili
bone marrow failure, lymphadenopathy, eosinophilia

forstørrede lymfekirtler (undertiden smertefuldt), knoglemarvssvigt, øget antal eosinofiler
enlarged lymph glands (sometimes painful), , failure of blood marrow, (increased eosinophil)

det kan skyldes lave niveauer af hvide blodlegemer i blodet. • knoglemarvssvigt.
this may be due to low levels of white cells in your blood. • bone marrow failure.

aplastisk anæmi, hæmolytisk anæmi, knoglemarvssvigt, leukopeni, neutropeni, trombocytopeni, agranulocytose
leukopenia, neutropenia, agranulocytosis, thrombocytopenia

ikke kendt: aplastisk anæmi, hæmolytisk anæmi, knoglemarvssvigt, leukopeni, neutropeni, agranulocytose, trombocytopeni
not known: aplastic anaemia, haemolytic anaemia, bone marrow failure, leukopenia, neutropenia, agranulocytosis, thrombocytopenia

længerevarende cytopenier (trombocytopeni, anæmi, neutropeni og leukopeni) og knoglemarvssvigt er blevet indberettet i tiden efter markedsføring.
during the post-marketing period prolonged cytopaenias (thrombocytopaenia, anaemia, neutropaenia and leukopaenia) and bone marrow failure have been reported.

det bør ikke anvendes til patienter, der ammer, eller til patienter, der før behandlingen har svært knoglemarvssvigt (for lavt antal hvide blodlegemer og blodplader).
it should not be used in patients who are breast-feeding, or in patients who have severe bone marrow depression (low white blood cell and platelet counts) before treatment.

hycamtin må ikke anvendes til patienter, der ammer, eller til patienter, der før behandlingen har svært knoglemarvssvigt (for lavt antal hvide blodlegemer og blodplader).
hycamtin must not be used in patients who are breast-feeding, or in patients who have severe bone marrow depression (low white blood cell and platelet counts) before treatment.

den almindeligste bivirkning hos patienter, der får paxene alene, er knoglemarvssvigt, der medfører svær mangel på hvide blodlegemer og på blodplader samt anæmi (mangel på røde blodlegemer).
the most common side effect in patients receiving paxene on its own is bone marrow suppression, which results in severe neutropenia (low white blood cells count), thrombocytopenia (low platelets count), and anaemia (low red blood cells count).

særlig forsigtighed tilrådes og risici/fordele bør nøje evalueres, hvis indgivelse af cladribine overvejes hos patienter med øget infektionsrisiko, manifest knoglemarvssvigt eller –infiltration, myelosuppressive forbehandlinger, såvel som hos patienter med formodet eller manifest nyre- og leverinsufficiens.
particular caution is advised and risks/benefits should be carefully evaluated if administration of cladribine is considered in patients with increased infection risk, manifested bone marrow failure or infiltration, myelosuppressive pre-treatments, as well as in patients with suspected or manifested renal and hepatic insufficiency.